Brief: BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib In Combination With Keytruda In NSCLC Patients Progressing On Immune Checkpoint Inhibitors

Oncoinvent ASA

15/01/2020 18:24

Jan 15 (Reuters) - BerGenBio ASA  BGBIO.OL :
    * BERGENBIO MEETS EFFICACY ENDPOINT FOR FIRST STAGE OF PHASE
II
TRIAL WITH AXL INHIBITOR BEMCENTINIB IN COMBINATION WITH
KEYTRUDA® IN NSCLC PATIENTS PROGRESSING ON IMMUNE CHECKPOINT
INHIBITORS
    * BERGENBIO ASA - FIRST STAGE CLINICAL EFFICACY ENDPOINT MET
FOR
PHASE II TRIAL COHORT
    * BERGENBIO ASA - FURTHER RESULTS FROM PHASE II WITH AXL
INHIBITOR
BEMCENTINIB IN COMBINATION WITH KEYTRUDA TRIAL ARE EXPECTED
DURING 2020

Source text for Eikon:  ID:nPn29nwDPa 
Further company coverage:  BGBIO.OL 

 ((Reuters.Briefs@thomsonreuters.com;;))